NYSE - Delayed Quote • USD
Nuvation Bio Inc. (NUVB)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.1 | -0.07 | -0.35 | -0.5 |
| Low Estimate | -0.12 | -0.1 | -0.39 | -0.62 |
| High Estimate | -0.07 | -0.05 | -0.3 | -0.44 |
| Year Ago EPS | -0.1 | -0.09 | -0.35 | -0.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | 1.1M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 3.3M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.11 | -0.11 | -0.1 |
| EPS Actual | -0.1 | -0.09 | -0.09 | -0.06 |
| Difference | 0 | 0.02 | 0.02 | 0.04 |
| Surprise % | 0.00% | 18.20% | 18.20% | 40.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | -0.07 | -0.35 | -0.5 |
| 7 Days Ago | -0.1 | -0.07 | -0.35 | -0.5 |
| 30 Days Ago | -0.1 | -0.08 | -0.37 | -0.54 |
| 60 Days Ago | -0.1 | -0.11 | -0.48 | -0.61 |
| 90 Days Ago | -0.1 | -0.11 | -0.48 | -0.61 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NUVB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 6.50% |
| Next Qtr. | 22.20% | -- | -- | 12.00% |
| Current Year | 0.00% | -- | -- | 5.30% |
| Next Year | -42.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 4/17/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/28/2024 |
| Upgrade | Jefferies: Hold to Buy | 3/27/2024 |
| Upgrade | BTIG: Neutral to Buy | 3/26/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/7/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/1/2024 |
Related Tickers
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
NXTC NextCure, Inc.
1.3500
+4.65%
ALGS Aligos Therapeutics, Inc.
0.7820
-4.40%
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%
BCAB BioAtla, Inc.
2.5400
+12.89%
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%
RGLS Regulus Therapeutics Inc.
2.4200
+6.61%
BNTC Benitec Biopharma Inc.
6.90
0.00%
ASMB Assembly Biosciences, Inc.
12.65
-5.31%
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%